HepaTx, Namocell, and Takara Bio USA complete second phase of collaboration on single cell analysis for cell therapy to treat late-stage liver diseases
Share this article Share this article PALO ALTO, Calif., March 12, 2021 /PRNewswire/ -- HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell's Single Cell Dispensers and Takara Bio's SMART-seq® kits to characterize HepaTx's novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library const...
Source: prnewswire.com